Company Name Kyowa Hakko Kirin Co., Ltd.

Representative Nobuo Hanai, President and CEO

(Code No.4151, First Section of TSE) Inquiries Niro Sakamoto, Executive Officer,

Corporate Communications Department Media Contact: +81-3-5205-7205

Investor Contact: +81-3-5205-7206

Concerning an Announcement by Kirin Holdings Company, Limited Tokyo, October 31, 2017 - Today Kirin Holdings Company, Limited, parent company of Kyowa Hakko Kirin Co., Ltd. (hereinafter, "Kyowa Hakko Kirin") has announced "Notice Regarding Termination of Joint Venture Agreement with Amgen Inc." However, this matter will not impact the business of Kyowa Hakko Kirin, and Kyowa Hakko Kirin will continue to develop, manufacture and sell pharmaceuticals licensed by Kirin-Amgen, Inc.

- 1 -

Kyowa Hakko Kirin Co. Ltd. published this content on 31 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 October 2017 06:52:04 UTC.

Original documenthttp://www.kyowa-kirin.com/news_releases/2017/pdf/e20171031_01.pdf

Public permalinkhttp://www.publicnow.com/view/709DB6D7EB28F8D988F9E672A57BF7EBF9F13B43